Specialized Consumer Services

BEAUTYFARM MED

Beauty 田园 Acquires Sisy Lyric to Enter High-End Beauty Market

Mei Li Tian Yuan Group Explores Breakthrough Strategies for the Beauty and Health Market

Mirabell Medical Beauty Health Repurchased 30,000 Shares for HK$605,100

BEAUTYFARM MED released FY2025 Q3 earnings on March 27, 2026 (BJT) with actual revenue of HKD 842.57 M and EPS of HKD 0.3771

BEAUTYFARM MED released FY2025 9 Months Earnings on March 27, 2026 (BJT) with actual revenue of HKD 2.422 B and EPS of HKD 1.1112

BEAUTYFARM MED released FY2025 Annual Earnings on March 27 After-Market (BJT), actual revenue HKD 3.279 B (forecast HKD 3.369 B), actual EPS HKD 1.4973 (forecast HKD 1.4984)

BEAUTYFARM MED released FY2025 Q4 earnings on March 27 After-Market (BJT), actual revenue HKD 857.11 M, actual EPS HKD 0.3836

BEAUTYFARM MED to Release FY2025 Annual Earnings on March 27 After-Market (BJT), Forecast Revenue HKD 3.427 B, EPS HKD 1.4889

CICC Raises Profit Forecast for Beautiful Territorial Medical Health for 2026

Beauty 田园 Medical Health Co. Repurchased 1,065,000 Shares

Kaiyuan Securities Upgrades Profit Forecast for Beautiful Garden Medical & Health

Beauty 田园 Healthcare Completes Acquisition of Shanghai Siyanli for 1.25 Billion

First Shanghai Securities Maintains Buy Rating on Beauty Farm Medical & Health with Target Price of HKD 43.70

Beauty 田园 Medical Health Repurchased Shares

MediBeaut Medical Health Conducts Stock Repurchase and Executive Increases Shares

Beauty Farmland Medical Health Repurchases 100,000 Shares

Beauty 田园 Medical Health Acquires Beauty and Healthcare Businesses in Dongguan and Zhuhai

China Everbright Securities Raises Forecast for Beautiful Countryside Health and Announces Large-Scale Shareholder Return Plan

Beauty 田园 Healthcare Acquires 100% of Sylph Beauty for 1.25 Billion Yuan

Beauty 田园 Healthcare to Dividend or Repurchase up to HKD 1.2 billion over Next 3 Years

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02373

Yesterday's closing, BEAUTYFARM MED's stock price rose slightly by 1.78%, closing at HKD 5.95, with a trading volume slightly exceeding HKD 67 million. The overall volatility was limited, indicating a continued tug-of-war between bulls and bears. The MACD daily bullish signal has begun to appear, but its strength is still insufficient, indicating the initial path of bullish momentum. From an industry perspective, national policies are increasingly leaning towards the health and medical field, and the development roadmap for new medical infrastructure is being expedited. The company's backbone support, provided through smart diagnostics and integration of the health industry chain, can attract long-term market attention. Especially under the backdrop of a relatively high domestic savings rate and increased awareness of healthcare, such enterprises possess potential growth value. From a technical outlook, the stock price has quickly consolidated horizontally at the 5-day moving average level before rising. The stock market has shown stability amid global macroeconomic uncertainties, with moderate trading volume revealing the market's patient recognition of medical stocks. If it can stabilize above the HKD 6 mark in the short term, the upward channel is expected to further expand. The short-term trend looks bullish, but the initial increase is not large, and the bullish signals in the short term are gradually showing positive enhancement. The medical sector may attract more funds under specific policy incentives; however, investors still need to consider the challenges of volatility on actual return limits. This article only provides technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances

Technical Forecast

Pre-market trend | BEAUTYFARM MED (2373.HK) slightly rises on 5/7, is the layout of medical pile foundation expanding again?

In a report released yesterday, from Guotai Haitong maintained a Buy rating on Beauty Farm Medical & Health Industry, Inc., with a price target of HK$34.49.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Beauty Farm Medical & Health Industry, Inc. has an analyst consensus of Strong Buy, with a price target consensus of HK$37.24.

Tip Ranks

Beauty Farm Medical & Health Industry, Inc. (2373) Gets a Buy from Guotai Haitong

Orient Securities has maintained a Buy rating on Beauty Farm Medical & Health Industry, Inc. (2373), setting a price target of HK$31.21. The company's shares closed at HK$20.34. Analyst consensus for the company is Strong Buy, with a higher price target consensus of HK$38.11.

Orient Securities Keeps Their Buy Rating on Beauty Farm Medical & Health Industry, Inc. (2373)

BEAUTYFARM MED announced its full-year results for the year ended December last year, with a revenue of RMB 3.001 billion, an increase of 16.7% year-on-year. The net profit was RMB 318 million, an increase of 39% year-on-year; earnings per share were RMB 1.38. A final dividend of HKD 0.72 was declared, compared to HKD 0.52 in the same period last year

AASTOCKS

"Performance" BEAUTYFARM MED's annual net profit is 318 million RMB, an increase of 39%, with a final dividend of 72 Hong Kong cents

A new patient-focused data model is providing sponsors with increased flexibility to access more comprehensive real-world evidence throughout the entire study process. PicnicHealth, a health tech company based in San Francisco, announced on March 26, 2026, that this innovative approach is enhancing non-interventional research capabilities. This development aims to unlock a wealth of valuable insights for sponsors, potentially transforming the study landscape.

Unusual Whales

PicnicHealth Launches ThumbPrint: A Patient-Anchored Alternative to Tokenization

Beauty Farm Aggregates RMB280 Million in Principal-Guaranteed Wealth Products, Triggering Disclosure

Beauty Farm Aggregates RMB280 Million in Principal-Guaranteed Wealth Products, Triggering Disclosure

GF Securities has reaffirmed its Buy rating for Beauty Farm Medical & Health Industry, Inc. (2373), setting a price target of HK$41.12. The overall analyst consensus for the company is a Strong Buy, with an average price target of HK$40.99.

GF Securities Sticks to Its Buy Rating for Beauty Farm Medical & Health Industry, Inc. (2373)

600000

BEAUTYFARM MED announced that on February 13th, its subsidiary Beijing Beilish used idle funds to subscribe to a principal-protected financial product from SPD Bank, with a total subscription amount of 80 million RMB and a term of 150 days

SPD Bank

BEAUTYFARM MED subsidiary subscribes to wealth management products worth 80 million RMB

BEAUTYFARM MED(02373.HK)

Pre-market trend | BEAUTYFARM MED (2373.HK) slightly rises on 5/7, is the layout of medical pile foundation expanding again?

Beauty Farm Medical & Health Industry, Inc. (2373) Gets a Buy from Guotai Haitong

Orient Securities Keeps Their Buy Rating on Beauty Farm Medical & Health Industry, Inc. (2373)

"Performance" BEAUTYFARM MED's annual net profit is 318 million RMB, an increase of 39%, with a final dividend of 72 Hong Kong cents

PicnicHealth Launches ThumbPrint: A Patient-Anchored Alternative to Tokenization

Beauty Farm Aggregates RMB280 Million in Principal-Guaranteed Wealth Products, Triggering Disclosure

GF Securities Sticks to Its Buy Rating for Beauty Farm Medical & Health Industry, Inc. (2373)

BEAUTYFARM MED subsidiary subscribes to wealth management products worth 80 million RMB